Paris-based EOS imaging has announced that the Galien Foundation has awarded it the Prix Galien in the Medical Device category.
EOS imaging Wins Prix Galien
1 min read Premium comments
Secondary
According to the company, “The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation that improves human health. The Prix Galien recognizes excellence in the future of medicine and is based on a jury of 50 healthcare experts.”
“It is awarded in six categories, including medical devices, drugs, research, eHealth, patient support, and dermatology. The award is presented to EOS imaging in recognition of its EOS system for 2D/3D low dose imaging and associated EOS apps suite of online 3D surgical planning solutions for spine, hip and knee surgeries.”
“We designed the EOS System specifically to address unmet needs in orthopedic imaging—providing high quality, full-body 2D and 3D images with less radiation exposure, as well as precise and complete patient data.”
“Subsequently, we built on this foundation to offer EOS-based online 3D surgical simulation, planning and control software solutions to help surgeons improve patient outcomes,” commented EOS Chief Executive Officer Marie Meynadier.
“We are proud to see EOS becoming a standard of care as our installed base continues to grow worldwide, and are honored that the Galien Foundation recognizes its contribution towards patient safety and improved orthopedic care.”
Marie Meynadier told OTW, “EOS adoption rate continues to increase worldwide, and it has prompted us to make major investments in the U.S. in 2017. We expect these activities to create further acceleration on the North American market in 2018.”
Editor’s Note: EOS is also a winner of the Orthopedics This Week Best Technology in Spine for 2016.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.